Day One

Wednesday, September 4, 2024

7:00 am Check-In & Breakfast

8:25 am Chair’s Opening Remarks

Highlights, Opportunities & Lessons from the Bispecific Clinical Landscape

8:30 am A Review of the Bispecific Landscape: The Past, The Present & The Future of Biologics


  • Reviewing drug and trial landscape
  • Discussing emerging trends in the landscape
  • Briefly outlining the future of the bispecific space

9:00 am Finetuning the Potency & Safety of 4-1BB Agonist Antibodies By Targeting the Membrane Proximal Region

  • Andy Tsun Co-Founder & Chief Scientific Officer, Biotheus.Inc.


  • Unique anti-4-1BB VHH that binds to the membrane proximal domain to maintain potency and reduce toxicity risk
  • CLDN18.2 x 4-1BB bispecific shows good safety and preliminary efficacy in CLDN18.2+ cancer patients
  • 4-1BB bispecific platform can be further optimized with unidirectional Fc effector function towards TAAs but not 4-1BB+ cells

9:30 am Delving into ABBV-383, a Novel Bispecific Antibody with Enhanced Tumor Targeting & Optimized T-cell Engagement in Multiple Myeloma

  • Jeremy Ross Scientific Director and Head of Precision Medicine, Hematology Oncology, Abbvie


  • Scientific rationale for high avidity tumor antigen binding coupled with low affinity CD3 T-cell engagement by ABBV-383
  • Translation of unique design attributes of ABBV-383 to the clinic
  • Clinical updates on ABBV-383 in patient with relapsed or refractory multiple myeloma

10:00 am Morning Break & Speed Networking


The ideal opportunity to get face-to-face with many of the brightest minds working in the bispecific field and introduce yourself to the attendees that you would like to have more in-depth conversations with.

11:30 am Bispecific Antibody Therapeutics in Immunology & Inflammation – Opportunities & Lessons for Success

  • Shanshan Xu Vice President - External Innovations, BioNTech

12:00 pm Deconstructing Endogenous T Cell Reactivities as Drivers of TCE Response & Resistance


  • Identifying how T cells in multiple myeloma patients respond to TCEs according to their cell state and TCR specificity
  • Linking inter-individual differences in the immune repertoire to clinical response
  • Leveraging TCE immune perturbations to establish predictive biomarkers and novel personalized cell therapies

12:05 pm Session Reserved for Cytiva

12:30 pm Lunch

Exploring the Latest Novel Formats for Widening the Applications of Bispecific Antibodies

1:30 pm XmAb541: A Selectivity Engineered XmAb 2+1 CLDN6 x CD3 Bispecific Antibody for Treatment of Ovarian Cancer & Other CLDN6+ Solid Tumors

  • Matthew Faber Senior Scientist - Protein and Antibody Engineer, Xencor


  • Xencor’s XmAb® platforms allow for the rapid development of therapeutic bispecific with novel formats/binding modes that engage T cells (xCD3, xCD28) or NK cells xNKp46, xNKG2D) or act though other mechanisms in oncology, autoimmune, and inflammatory disorders.
  • Analysis of genomic/transcriptomic data to identify CLDN6 as an antigen with high expression in ovarian cancer tumors with very little expression in normal tissues & overcoming binding selectivity requirements as other similar CLDNs are expressed in normal tissue.
  • Target selection and preclinical development of XmAb541, a CLDN6xCD3 2+1 bispecific protein for treating patients with ovarian cancer and other solid tumor indications.

2:00 pm Looking to Satisfy the Growing Demand of Capacity & Capabilities for Biologics


  • Biologics landscape trends and analysis
  • Outsourcing or In-House?
  • Quick overview and updates on BSP’s services and solutions

2:15 pm Leveraging AzymetricTM to Optimally Format T-Cell Engagers & Bispecific ADCs


  • Azymetric provides a robust Fc heterodimer solution enabling high throughput functional screening of multispecific antibody panels to select those optimally formatted for a therapeutic application
  • The most advanced Azymetric molecule, zanidatamab, a bi-paratopic anti-HER2 antibody undergoing pivotal clinical studies, exemplifies the opportunity afforded to enhance antitumor responses beyond that achieved through combination of antibody components
  • Data illustrating the utility of Azymetric for two additional applications will be shared: (A) Development of multi-functional T-cell engagers including incorporation of conditional co-stimulation and (B) Format screening of bispecific antibodies to support delivery of small molecule payloads simultaneously to two independently expressed cancer targets

2:45 pm Generating CD8-Selective T Cell Engagers

3:00 pm Afternoon Break & Poster Session


This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of bispecific experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters displaying cutting-edge work from drug discovery right through to exciting clinical trial updates.

4:00 pm Delving into Chugai Pharmaceutical’s Multidimensional Optimization Process to Improve Both the Therapeutic Potential & the Manufacturability


  • Exploring FAST-Ig™, designed for efficient production of bispecific antibodies and ACTFc®, to improve antibody pharmacokinetics
  • Applying these unique technology platforms to NXT007, a next-generation version of emicizumab for hemophilia A
  • Discussing future directions for creating novel bispecific antibodies and beyond

4:30 pm Session Reserved for Nona

4:45 pm Eliciting Potent & Safe Innate & Adaptive Immune Responses to Cancer with Bispecific Antibody Approaches to CD47 or CD28

  • Walter Ferlin Chief Scientific Officer, Light chain Biosciences


  • Bispecific antibodies (bsAbs) were developed to selectively target CD47 on tumor cells and regulate CD28-mediated T-cell co-stimulation, overcoming tolerability challenges encountered with monoclonal antibody (mAb) approaches while avoiding systemic toxicities associated with CD47 and CD28 targeting, respectively
  • CD47bsAbs with fully competent IgG1-Fc domains show potent anti-tumor activity in vitro and in vivo, prompting human trials due to favorable tolerability and PK profiles
  • The lead preclinical CD28-program, a PD-L1xCD28 bsAb, demonstrates anti-tumor efficacy and synergizes with TCEs in controlling tumor growth, showing promising PK and tolerability profiles for clinical translation

5:15 pm Chair’s Closing remarks